
Joseph H. Antin, MD, Dana-Farber Cancer Institute
Advertisement
Articles by Joseph H. Antin, MD, Dana-Farber Cancer Institute
Advertisement
Latest Updated Articles
Risk Factors for Graft-vs-Host DiseaseJune 19th 2020
Special Transplant SituationsJune 19th 2020
Members of the Transplant TeamJune 19th 2020
Timing of Referral for TransplantJune 19th 2020
Graft-vs-Host Disease Prophylaxis Clinical TrialsJune 19th 2020
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Priority Review to Sonesitatug Vedotin in CLDN18.2+ Gastroesophageal Cancer
2
EC Approves Extended Cemiplimab Dosing in Skin, Lung, and Cervical Cancers
3
Dose Optimization, Evidentiary Bars, and Patient Selection Shape Trial Design in EGFR- and HER2-Mutant NSCLC
4
Defining High-Risk Localized Prostate Cancer and the DASL-HiCaP Trial
5








